About AVT
Browse Articles
Customer Services


Dengue vaccine development and dengue viral neutralization and enhancement assays

Xia Jin, Olivia Tono Block, Robert Rose, Jacob Schlesinger

Corresponding author name: Xia Jin
Corresponding author e-mail: xia_jin@urmc.rochester.edu

Citation: Antiviral Therapy 2009; 14:739-749
doi: 10.3851/IMP1288

Date accepted: 01 June 2009
Date published online: 08 October 2009


Dengue fever is a major tropical infectious disease that affects 50–100 million people each year. Its complications, namely dengue haemorrhagic fever and dengue shock syndrome, disproportionately afflict children and young adults. The primary goal of several vaccines now in development is to elicit protective neutralizing antibody responses; however, the exact definition of such responses remain unclear. Here, we review briefly the historical aspects of dengue vaccine development and current candidate dengue vaccines, and discuss various laboratory assays for gauging the neutralizing antibody responses to infection or vaccination, or both. We conclude that modification of current neutralization assays is required to improve the correlation between neutralization end point determinations and protection against secondary heterotypic dengue infections.


Copyright © 2019 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.